|
|||||
|
|
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose |
|
| Authors: | P. Rigo P. Paulus B. J. Kaschten R. Hustinx T. Bury G. Jerusalem T. Benoit J. Foidart-Willems |
| Affiliation: | (1) Division of Nuclear Medicine, University Hospital, Sart Tilman, B.35, B-4000 Liege 1, Belgium;(2) Cyclotron Research Centre, University of Liege and Division of Neurosurgery, University Hospital, Sart Tilman, Liege, Belgium;(3) Division of Pneumology, University Hospital, Sart Tilman, Liege, Belgium;(4) Division of Onco-Hematology, University Hospital, Sart Tilman, Liege, Belgium |
| Abstract: | Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved. |
| Keywords: | Positron emission tomography Fluorine-18 fluorodeoxyglucose Oncology |
| 本文献已被 SpringerLink 等数据库收录！ | |